Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

Letter to the editor.

van der Werf MJ, Rosales-Klintz S, de Vlas SJ.

Clin Infect Dis. 2019 Jun 3. pii: ciz458. doi: 10.1093/cid/ciz458. [Epub ahead of print] No abstract available.

PMID:
31161216
2.

Whole-Genome Sequencing as Tool for Investigating International Tuberculosis Outbreaks: A Systematic Review.

van der Werf MJ, Ködmön C.

Front Public Health. 2019 Apr 17;7:87. doi: 10.3389/fpubh.2019.00087. eCollection 2019.

3.

Role and value of whole genome sequencing in studying tuberculosis transmission.

Nikolayevskyy V, Niemann S, Anthony R, van Soolingen D, Tagliani E, Ködmön C, van der Werf MJ, Cirillo DM.

Clin Microbiol Infect. 2019 Apr 11. pii: S1198-743X(19)30124-7. doi: 10.1016/j.cmi.2019.03.022. [Epub ahead of print] Review.

PMID:
30980928
4.

Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014.

Karo B, Kohlenberg A, Hollo V, Duarte R, Fiebig L, Jackson S, Kearns C, Ködmön C, Korzeniewska-Kosela M, Papaventsis D, Solovic I, van Soolingen D, van der Werf MJ.

Euro Surveill. 2019 Mar;24(12). doi: 10.2807/1560-7917.ES.2019.24.12.1800392.

5.

Will we reach the Sustainable Development Goals target for tuberculosis in the European Union/European Economic Area by 2030?

Merk H, Ködmön C, van der Werf MJ.

Euro Surveill. 2019 Mar;24(12). doi: 10.2807/1560-7917.ES.2019.24.12.1900153.

6.

Molecular and genomic typing for tuberculosis surveillance: A survey study in 26 European countries.

Andrés M, van der Werf MJ, Ködmön C, Albrecht S, Haas W, Fiebig L; Survey study group.

PLoS One. 2019 Mar 13;14(3):e0210080. doi: 10.1371/journal.pone.0210080. eCollection 2019.

7.

Guidance for programmatic management of latent tuberculosis infection in the European Union/European Economic Area.

Rosales-Klintz S, Bruchfeld J, Haas W, Heldal E, Houben RMGJ, van Kessel F, Mandelbaum M, Matteelli A, Migliori GB, Oordt-Speets A, Solovic I, Vašáková M, Verver S, de Vlas SJ, Vonk Noordegraaf-Schouten MJM, de Vries G, Zenner D, van der Werf MJ.

Eur Respir J. 2019 Jan 17;53(1). pii: 1802077. doi: 10.1183/13993003.02077-2018. Print 2019 Jan. No abstract available.

PMID:
30655449
8.

Factors associated with non-adherence during tuberculosis treatment among patients treated with DOTS strategy in Jayapura, Papua Province, Indonesia.

Ruru Y, Matasik M, Oktavian A, Senyorita R, Mirino Y, Tarigan LH, van der Werf MJ, Tiemersma E, Alisjahbana B.

Glob Health Action. 2018;11(1):1510592. doi: 10.1080/16549716.2018.1510592.

9.

"Treatment is of primary importance, and social assistance is secondary": A qualitative study on the organisation of tuberculosis (TB) care and patients' experience of starting and staying on TB treatment in Riga, Latvia.

Kielmann K, Vidal N, Riekstina V, Krutikov M, van der Werf MJ, Biraua E, Duric P, Moore DAJ.

PLoS One. 2018 Oct 17;13(10):e0203937. doi: 10.1371/journal.pone.0203937. eCollection 2018.

10.

European Union standard for tuberculosis care on treatment of multidrug-resistant tuberculosis following new World Health Organization recommendations.

Migliori GB, Sotgiu G, Rosales-Klintz S, van der Werf MJ.

Eur Respir J. 2018 Nov 8;52(5). pii: 1801617. doi: 10.1183/13993003.01617-2018. Print 2018 Nov. No abstract available.

PMID:
30209200
11.

Effectiveness of service models and organisational structures supporting tuberculosis identification and management in hard-to-reach populations in countries of low and medium tuberculosis incidence: a systematic review.

Heuvelings CC, Greve PF, de Vries SG, Visser BJ, Bélard S, Janssen S, Cremers AL, Spijker R, Shaw E, Hill RA, Zumla A, Sandgren A, van der Werf MJ, Grobusch MP.

BMJ Open. 2018 Sep 8;8(9):e019642. doi: 10.1136/bmjopen-2017-019642.

12.

Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.

Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T, Seddon JA, Menzies D, Turkova A, Achar J, Amanullah F, Barry P, Becerra M, Chan ED, Chan PC, Ioana Chiotan D, Crossa A, Drobac PC, Fairlie L, Falzon D, Flood J, Gegia M, Hicks RM, Isaakidis P, Kadri SM, Kampmann B, Madhi SA, Marais E, Mariandyshev A, Méndez-Echevarría A, Moore BK, Nargiza P, Ozere I, Padayatchi N, Ur-Rehman S, Rybak N, Santiago-Garcia B, Shah NS, Sharma S, Shim TS, Skrahina A, Soriano-Arandes A, van den Boom M, van der Werf MJ, van der Werf TS, Williams B, Yablokova E, Yim JJ, Furin J, Hesseling AC; Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in MDR-TB.

PLoS Med. 2018 Jul 11;15(7):e1002591. doi: 10.1371/journal.pmed.1002591. eCollection 2018 Jul.

13.

Defining a migrant-inclusive tuberculosis research agenda to end TB.

Shete PB, Boccia D, Dhavan P, Gebreselassie N, Lönnroth K, Marks S, Matteelli A, Posey DL, van der Werf MJ, Winston CA, Lienhardt C.

Int J Tuberc Lung Dis. 2018 Aug 1;22(8):835-843. doi: 10.5588/ijtld.17.0503. Review. Erratum in: Int J Tuberc Lung Dis. 2018 Oct 1;22(10):1244.

14.

Cross-border outbreak of extensively drug-resistant tuberculosis linked to a university in Romania.

Popovici O, Monk P, Chemtob D, Chiotan D, Freidlin PJ, Groenheit R, Haanperä M, Homorodean D, Mansjö M, Robinson E, Rorman E, Smith G, Soini H, Van Der Werf MJ.

Epidemiol Infect. 2018 May;146(7):824-831. doi: 10.1017/S095026881800047X.

PMID:
29769160
15.

ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update.

Migliori GB, Sotgiu G, Rosales-Klintz S, Centis R, D'Ambrosio L, Abubakar I, Bothamley G, Caminero JA, Cirillo DM, Dara M, de Vries G, Aliberti S, Dinh-Xuan AT, Duarte R, Midulla F, Solovic I, Subotic DR, Amicosante M, Correia AM, Cirule A, Gualano G, Kunst H, Palmieri F, Riekstina V, Tiberi S, Verduin R, van der Werf MJ.

Eur Respir J. 2018 May 17;51(5). pii: 1702678. doi: 10.1183/13993003.02678-2017. Print 2018 May.

PMID:
29678945
16.

The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review.

Greenaway C, Pareek M, Abou Chakra CN, Walji M, Makarenko I, Alabdulkarim B, Hogan C, McConnell T, Scarfo B, Christensen R, Tran A, Rowbotham N, van der Werf MJ, Noori T, Pottie K, Matteelli A, Zenner D, Morton RL.

Euro Surveill. 2018 Apr;23(14). doi: 10.2807/1560-7917.ES.2018.23.14.17-00543.

17.

The effectiveness and cost-effectiveness of screening for active tuberculosis among migrants in the EU/EEA: a systematic review.

Greenaway C, Pareek M, Abou Chakra CN, Walji M, Makarenko I, Alabdulkarim B, Hogan C, McConnell T, Scarfo B, Christensen R, Tran A, Rowbotham N, Noori T, van der Werf MJ, Pottie K, Matteelli A, Zenner D, Morton RL.

Euro Surveill. 2018 Apr;23(14). doi: 10.2807/1560-7917.ES.2018.23.14.17-00542.

18.

EUSeqMyTB to set standards and build capacity for whole genome sequencing for tuberculosis in the EU.

Tagliani E, Cirillo DM, Ködmön C, van der Werf MJ; EUSeqMyTB Consortium.

Lancet Infect Dis. 2018 Apr;18(4):377. doi: 10.1016/S1473-3099(18)30132-4. Epub 2018 Mar 21. No abstract available.

PMID:
29582760
19.

Time-and-motion tool for the assessment of working time in tuberculosis laboratories: a multicentre study.

Mathys V, Roycroft E, Raftery P, Groenheit R, Folkvardsen DB, Homorodean D, Vasiliauskiene E, Vasiliauskaite L, Kodmon C, van der Werf MJ, Drobniewski F, Nikolayevskyy V.

Int J Tuberc Lung Dis. 2018 Apr 1;22(4):444-451. doi: 10.5588/ijtld.17.0564.

20.

Screening of migrants for tuberculosis identifies patients with multidrug-resistant tuberculosis but is not sufficient.

Helbling P, Kröger S, Haas W, Brusin S, Cirillo DM, Groenheit R, Guthmann JP, Soini H, Hendrickx D, van der Werf MJ.

Clin Microbiol Infect. 2018 Aug;24(8):918-919. doi: 10.1016/j.cmi.2018.03.015. Epub 2018 Mar 17. No abstract available.

21.

A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study.

Walker TM, Merker M, Knoblauch AM, Helbling P, Schoch OD, van der Werf MJ, Kranzer K, Fiebig L, Kröger S, Haas W, Hoffmann H, Indra A, Egli A, Cirillo DM, Robert J, Rogers TR, Groenheit R, Mengshoel AT, Mathys V, Haanperä M, Soolingen DV, Niemann S, Böttger EC, Keller PM; MDR-TB Cluster Consortium.

Lancet Infect Dis. 2018 Apr;18(4):431-440. doi: 10.1016/S1473-3099(18)30004-5. Epub 2018 Jan 8. Erratum in: Lancet Infect Dis. 2018 Jan 10;:.

22.

Childhood multidrug-resistant tuberculosis in the European Union and European Economic Area: an analysis of tuberculosis surveillance data from 2007 to 2015.

Ködmön C, van den Boom M, Zucs P, van der Werf MJ.

Euro Surveill. 2017 Nov;22(47). doi: 10.2807/1560-7917.ES.2017.22.47.17-00103.

23.

Closing the gap in surveillance of tuberculosis and HIV co-infection: a European perspective on the need for clinician-public health alliances.

van der Werf MJ, Sotgiu G, Dara M.

Eur Respir J. 2017 Nov 16;50(5). pii: 1701758. doi: 10.1183/13993003.01758-2017. Print 2017 Nov. No abstract available.

24.

Aiming for zero tuberculosis transmission in low-burden countries.

Marais BJ, Walker TM, Cirillo DM, Raviglione M, Abubakar I, van der Werf MJ, Boehme C, Niemann S, Castro KG, Zumla A, Sintchenko V, Crook DW.

Lancet Respir Med. 2017 Nov;5(11):846-848. doi: 10.1016/S2213-2600(17)30382-X. Epub 2017 Oct 13. No abstract available.

PMID:
29033268
25.

Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis.

Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ.

Ann Intern Med. 2017 Aug 15;167(4):248-255. doi: 10.7326/M17-0609. Epub 2017 Aug 1. Review.

26.

Will the European Union reach the United Nations Millennium declaration target of a 50% reduction of tuberculosis mortality between 1990 and 2015?

van der Werf MJ, Bonfigli S, Hruba F.

BMC Public Health. 2017 Jul 6;17(1):629. doi: 10.1186/s12889-017-4544-9.

27.

Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.

van der Werf MJ, Ködmön C, Catchpole M.

Eur Respir J. 2017 Jun 1;49(6). pii: 1700463. doi: 10.1183/13993003.00463-2017. Print 2017 Jun. No abstract available.

28.

Tuberculosis in migrants in low-incidence countries: epidemiology and intervention entry points.

Lönnroth K, Mor Z, Erkens C, Bruchfeld J, Nathavitharana RR, van der Werf MJ, Lange C.

Int J Tuberc Lung Dis. 2017 Jun 1;21(6):624-637. doi: 10.5588/ijtld.16.0845. Review.

PMID:
28482956
29.

Health system factors influencing management of multidrug-resistant tuberculosis in four European Union countries - learning from country experiences.

de Vries G, Tsolova S, Anderson LF, Gebhard AC, Heldal E, Hollo V, Cejudo LS, Schmid D, Schreuder B, Varleva T, van der Werf MJ.

BMC Public Health. 2017 Apr 19;17(1):334. doi: 10.1186/s12889-017-4216-9.

30.

Tuberculosis notification rate decreases faster in residents of native origin than in residents of foreign origin in the EU/EEA, 2010 to 2015.

Hollo V, Beauté J, Ködmön C, van der Werf MJ.

Euro Surveill. 2017 Mar 23;22(12). pii: 30486. doi: 10.2807/1560-7917.ES.2017.22.12.30486.

31.

Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union.

van der Werf MJ, Hollo V, Ködmön C, Dara M, Catchpole M.

Eur Respir J. 2017 Mar 22;49(3). pii: 1601992. doi: 10.1183/13993003.01992-2016. Print 2017 Mar. No abstract available.

32.

Effectiveness of interventions for diagnosis and treatment of tuberculosis in hard-to-reach populations in countries of low and medium tuberculosis incidence: a systematic review.

Heuvelings CC, de Vries SG, Greve PF, Visser BJ, Bélard S, Janssen S, Cremers AL, Spijker R, Shaw B, Hill RA, Zumla A, Sandgren A, van der Werf MJ, Grobusch MP.

Lancet Infect Dis. 2017 May;17(5):e144-e158. doi: 10.1016/S1473-3099(16)30532-1. Epub 2017 Mar 11. Review.

PMID:
28291722
33.

Barriers and facilitators to the uptake of tuberculosis diagnostic and treatment services by hard-to-reach populations in countries of low and medium tuberculosis incidence: a systematic review of qualitative literature.

de Vries SG, Cremers AL, Heuvelings CC, Greve PF, Visser BJ, Bélard S, Janssen S, Spijker R, Shaw B, Hill RA, Zumla A, van der Werf MJ, Sandgren A, Grobusch MP.

Lancet Infect Dis. 2017 May;17(5):e128-e143. doi: 10.1016/S1473-3099(16)30531-X. Epub 2017 Mar 11. Review.

PMID:
28291721
34.

Multidrug-resistant tuberculosis and migration to Europe.

van der Werf MJ, Hollo V, Ködmön C.

Clin Microbiol Infect. 2017 Aug;23(8):578-579. doi: 10.1016/j.cmi.2017.02.017. Epub 2017 Feb 20. No abstract available.

35.

Fighting tuberculosis in the EU/EEA: towards the new European Union standards on tuberculosis care.

Sotgiu G, Beer N, Aliberti S, Migliori GB, van der Werf MJ.

Eur Respir J. 2016 Nov;48(5):1278-1281. doi: 10.1183/13993003.01459-2016. No abstract available.

36.

Tuberculosis and HIV coinfection in Europe: looking at one reality from two angles.

van der Werf MJ, Ködmön C, Zucs P, Hollo V, Amato-Gauci AJ, Pharris A.

AIDS. 2016 Nov 28;30(18):2845-2853.

37.

Identifying components for programmatic latent tuberculosis infection control in the European Union.

Sandgren A, Vonk Noordegraaf-Schouten JM, Oordt-Speets AM, van Kessel GB, de Vlas SJ, van der Werf MJ.

Euro Surveill. 2016 Aug 25;21(34). doi: 10.2807/1560-7917.ES.2016.21.34.30325.

38.

Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review.

Stuurman AL, Vonk Noordegraaf-Schouten M, van Kessel F, Oordt-Speets AM, Sandgren A, van der Werf MJ.

BMC Infect Dis. 2016 Jun 8;16:257. doi: 10.1186/s12879-016-1549-4. Review.

39.

Initiation and completion rates for latent tuberculosis infection treatment: a systematic review.

Sandgren A, Vonk Noordegraaf-Schouten M, van Kessel F, Stuurman A, Oordt-Speets A, van der Werf MJ.

BMC Infect Dis. 2016 May 17;16:204. doi: 10.1186/s12879-016-1550-y.

40.

External Quality Assessment for Tuberculosis Diagnosis and Drug Resistance in the European Union: A Five Year Multicentre Implementation Study.

Nikolayevskyy V, Hillemann D, Richter E, Ahmed N, van der Werf MJ, Kodmon C, Drobniewski F, Ruesch-Gerdes S; ERLTB-Net Network.

PLoS One. 2016 Apr 7;11(4):e0152926. doi: 10.1371/journal.pone.0152926. eCollection 2016.

41.

Public health needs of migrants, refugees and asylum seekers in Europe, 2015: Infectious disease aspects.

Semenza JC, Carrillo-Santisteve P, Zeller H, Sandgren A, van der Werf MJ, Severi E, Pastore Celentano L, Wiltshire E, Suk JE, Dinca I, Noori T, Kramarz P.

Eur J Public Health. 2016 Jun;26(3):372-3. doi: 10.1093/eurpub/ckw023. Epub 2016 Apr 6. No abstract available.

PMID:
27053729
42.

Tuberculosis infection control in health facilities in Lithuania: lessons learnt from a capacity support project.

Turusbekova N, Ljungqvist I, Davidavičiene E, Mikaityte J, van der Werf MJ.

Public Health Action. 2016 Mar 21;6(1):22-4. doi: 10.5588/pha.15.0060.

43.
44.

Impact of migration on tuberculosis epidemiology and control in the EU/EEA.

van der Werf MJ, Zellweger JP.

Euro Surveill. 2016;21(12). doi: 10.2807/1560-7917.ES.2016.21.12.30174. No abstract available.

45.

The effect of migration within the European Union/European Economic Area on the distribution of tuberculosis, 2007 to 2013.

Hollo V, Kotila SM, Ködmön C, Zucs P, van der Werf MJ.

Euro Surveill. 2016;21(12). doi: 10.2807/1560-7917.ES.2016.21.12.30171.

46.

Interrupted BCG vaccination is a major threat to global child health.

Marais BJ, Seddon JA, Detjen AK, van der Werf MJ, Grzemska M, Hesseling AC, Curtis N, Graham SM; WHO Child TB Subgroup.

Lancet Respir Med. 2016 Apr;4(4):251-3. doi: 10.1016/S2213-2600(16)00099-0. Epub 2016 Mar 23. Review. No abstract available.

PMID:
27016867
47.

Tackling tuberculosis in migrants.

van der Werf MJ, Kramarz P.

Lancet Infect Dis. 2016 Aug;16(8):877-8. doi: 10.1016/S1473-3099(16)00148-1. Epub 2016 Mar 22. No abstract available.

48.

Strengthening TB infection control in specialized health facilities in Romania--using a participatory approach.

Turusbekova N, Popa C, Dragos M, van der Werf MJ, Dinca I.

Public Health. 2016 Feb;131:75-81. doi: 10.1016/j.puhe.2015.10.031. Epub 2016 Jan 15.

49.

Impact of HIV infection on treatment outcome of tuberculosis in Europe.

Karo B, Krause G, Hollo V, van der Werf MJ, Castell S, Hamouda O, Haas W.

AIDS. 2016 Apr 24;30(7):1089-98. doi: 10.1097/QAD.0000000000001016.

PMID:
26752278
50.

Tuberculosis treatment outcome in the European Union and European Economic Area: an analysis of surveillance data from 2002-2011.

Karo B, Hauer B, Hollo V, van der Werf MJ, Fiebig L, Haas W.

Euro Surveill. 2015;20(49). doi: 10.2807/1560-7917.ES.2015.20.49.30087. Erratum in: Euro Surveill. 2015;20(50). doi: 10.2807/1560-7917.ES.2015.20.50.30092.

Supplemental Content

Loading ...
Support Center